SCHEMBL3564606

SCHEMBL3564606

Cc1ccccc1-c1ccc2c(c1)/C(=C/Nc1ccc(CC#N)cc1)C(=O)NC2=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.37
MEN1 O00255 1/20 0.37
ABCB1 P08183 2/20 0.35
ABCG2 Q9UNQ0 2/20 0.35
GRIA1 P42261 1/20 0.34
CACNG8 Q8WXS5 1/20 0.34
FFAR1 O14842 3/20 0.34
FFAR4 Q5NUL3 1/20 0.33
PPARG P37231 1/20 0.33
GSK3A P49840 1/20 0.33
CHEK1 O14757 2/20 0.32
ABCC1 P33527 1/20 0.32
PARP1 P09874 1/20 0.32
PARP2 Q9UGN5 1/20 0.32
AR P10275 1/20 0.32
ALK Q9UM73 1/20 0.32
PIK3CA P42336 2/20 0.31
PIK3CG P48736 2/20 0.31
NPC1 O15118 1/20 0.31
THRB P10828 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3564609 1.00 KMT2A (0.37) KMT2AMEN1ABCB1ABCG2GRIA1
SCHEMBL3564791 0.89 PTPRC (0.40) KMT2AMEN1PARP1ALKPIK3CA
SCHEMBL3564788 0.89 PTPRC (0.40) KMT2AMEN1PARP1ALKPIK3CA
SCHEMBL3566338 0.89 PIK3CA (0.41) KMT2AMEN1ABCB1ABCG2CHEK1
SCHEMBL3566337 0.89 PIK3CA (0.41) KMT2AMEN1ABCB1ABCG2CHEK1
SCHEMBL3567881 0.88 PKM (0.37) KMT2AMEN1GSK3ANPC1
SCHEMBL3567883 0.88 PKM (0.37) KMT2AMEN1GSK3ANPC1
SCHEMBL3565722 0.88 KMT2A (0.37) KMT2AMEN1ABCB1ABCG2CHEK1
SCHEMBL3565725 0.88 KMT2A (0.37) KMT2AMEN1ABCB1ABCG2CHEK1
SCHEMBL3576042 0.87 CHEK1 (0.45) KMT2AMEN1GSK3ACHEK1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7713994-B2 Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo,1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihyro-3 (2H)-isoquinolones and methods of use thereof WYETH LLC (US) 2010-05-11 US claimed
US-20080085890-A1 Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3 (2H)-isoquinolones and methods of use thereof WYETH (US) 2008-04-10 US claimed
US-7713994-B2 Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo,1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihyro-3 (2H)-isoquinolones and methods of use thereof WYETH LLC (US) 2010-05-11 US disclosed
EP-1963273-A2 SUBSTITUTED ISOQUINOLINE-1,3(2H,4H)-DIONES, 1-THIOXO-1,4-DIHYDRO-2H-ISOQUINOLINE-3-ONES AND 1,4-DIHYDRO-3(2H)-ISOQUINOLONES AND USE THEREOF AS KINASE INHIBITORS Wyeth a Corporation of the State of Delaware (US) 2008-09-03 EP disclosed
US-20080085890-A1 Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3 (2H)-isoquinolones and methods of use thereof WYETH (US) 2008-04-10 US disclosed
WO-2007075783-A2 SUBSTITUTED ISOQUINOLINE-1,3(2H,4H)-DIONES, 1-THIOXO-1,4-DIHYDRO-2H-ISOQUINOLINE-3-ONES AND 1,4-DIHYDRO-3(2H)-ISOQUINOLONES AND USE THEREOF AS KINASE INHIBITOR WYETH (US) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080085890-A1 Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3 (2H)-isoquinolones and methods of use thereof SULT1E1, RECQL, HAX1 KMT2A 1053/4885MEN1 1015/4885ABCB1 299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.